Literature DB >> 2007649

Isolation of Chlamydia pneumoniae from the lungs of patients infected with the human immunodeficiency virus.

M H Augenbraun1, P M Roblin, K Chirgwin, D Landman, M R Hammerschlag.   

Abstract

Chlamydia pneumoniae is being recognized as a common cause of respiratory tract infections. Bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients were examined by culture for this pathogen. Of 50 specimens examined, 5 (10%) were positive for C. pneumoniae. Four of these (80%) were also positive for other pathogens frequently implicated as causes of respiratory disease in this patient population. C. pneumoniae may frequently inhabit the respiratory tracts of human immunodeficiency virus-infected individuals.

Entities:  

Mesh:

Year:  1991        PMID: 2007649      PMCID: PMC269777          DOI: 10.1128/jcm.29.2.401-402.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

Authors:  K Chirgwin; P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Role of cell-mediated immunity in the resolution of secondary chlamydial genital infection in guinea pigs infected with the agent of guinea pig inclusion conjunctivitis.

Authors:  R G Rank; L S Soderberg; M M Sanders; B E Batteiger
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

3.  Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically.

Authors:  J T Grayston; V K Diwan; M Cooney; S P Wang
Journal:  Arch Intern Med       Date:  1989-01

4.  Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland.

Authors:  M Kleemola; P Saikku; R Visakorpi; S P Wang; J T Grayston
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

5.  In vitro drug susceptibility of Chlamydia sp. strain TWAR.

Authors:  C C Kuo; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

6.  Prevalence of Chlamydia trachomatis lung infection in patients with acquired immune deficiency syndrome.

Authors:  J V Moncada; J Schachter; C Wofsy
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

7.  Chlamydia trachomatis pneumonia in an HIV-seropositive patient.

Authors:  F P Kroon; J W van 't Wout; H T Weiland; R van Furth
Journal:  N Engl J Med       Date:  1989-03-23       Impact factor: 91.245

8.  Pneumonia due to chlamydia trachomatis in an immunocompromised adult.

Authors:  J I Ito; K A Comess; E R Alexander; H R Harrison; C G Ray; J Kiviat; R E Sobonya
Journal:  N Engl J Med       Date:  1982-07-08       Impact factor: 91.245

9.  Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection.

Authors:  K H Ramsey; L S Soderberg; R G Rank
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

10.  Chlamydia trachomatis infection as a cause of pneumonia after human marrow transplantation.

Authors:  J D Meyers; R C Hackman; W E Stamm
Journal:  Transplantation       Date:  1983-08       Impact factor: 4.939

  10 in total
  14 in total

1.  Laboratory diagnosis of Chlamydia pneumoniae infections.

Authors:  R W Peeling
Journal:  Can J Infect Dis       Date:  1995-07

Review 2.  Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis.

Authors:  S J Bourke; N F Lightfoot
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

3.  Chlamydia pneumoniae.

Authors:  T J Marrie
Journal:  Thorax       Date:  1993-01       Impact factor: 9.139

4.  Chlamydial respiratory infections.

Authors:  S J Bourke
Journal:  BMJ       Date:  1993-05-08

Review 5.  Bronchoscopic diagnosis of pneumonia.

Authors:  V S Baselski; R G Wunderink
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

6.  Chlamydia pneumoniae respiratory infections among patients infected with the human immunodeficiency virus.

Authors:  U V Comandini; P Maggi; P Santopadre; R Monno; G Angarano; V Vullo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-10       Impact factor: 3.267

7.  Roles of interleukin-12 and gamma interferon in murine Chlamydia pneumoniae infection.

Authors:  Y Geng; K Berencsi; Z Gyulai; T Valyi-Nagy; E Gonczol; G Trinchieri
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

8.  Chlamydia pneumoniae seroprevalence in immunocompetent and immunocompromised populations in Milan.

Authors:  F Blasi; R Cosentini; M C Schoeller; A Lupo; L Allegra
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

9.  Use of lambda phage DNA as a hybrid internal control in a PCR-enzyme immunoassay to detect Chlamydia pneumoniae.

Authors:  D G Pham; G E Madico; T C Quinn; M J Enzler; T F Smith; C A Gaydos
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

10.  Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment.

Authors:  K Laitinen; A L Laurila; M Leinonen; P Saikku
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.